Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC dextromethorphan abuse potential

Executive Summary

Will be addressed by the Drug Abuse Advisory Committee at its July 14 meeting. An August 1990 review of the antitussive ingredient dextromethorphan (A. H. Robins' Robitussin) prompted a request by the committee for more epidemiologic data on its abuse. The morning of July 15, the committee "will discuss procedures and policies for, and approaches to, the study of hallucinogenic drugs." The afternoon session is closed to the public.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel